The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy

Biomaterials

Volumn 35, Issue 1, 2014, Pages 316-326

  Shen, Jia ^a,b   Song, Guosheng ^c   An, Man ^a   Li, Xianqian ^d   Wu, Ning ^d   Ruan, Kangcheng ^a   Hu, Junqing ^c   Hu, Ronggui ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c DONGHUA UNIVERSITY   (China)

^d Xuhui Central Hospital   (China)

Author keywords

Anti tumor activity; Apoptotic cell death; Bortezomib; Drug delivery; Mesoporous silica; NSCLC

Indexed keywords

ANTI-TUMOR ACTIVITIES; APOPTOTIC CELL DEATH; BORTEZOMIB; MESOPOROUS SILICA; NSCLC;

CELL DEATH; CHEMOTHERAPY; DRUG DELIVERY; DRUG DOSAGE; NANOSPHERES; TUMORS;

ENZYME INHIBITION;

BORTEZOMIB; CASPASE 3; NANOSPHERE; PROTEIN P53; SILICON DIOXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER THERAPY; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; ENCAPSULATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; WILD TYPE;

ANTI-TUMOR ACTIVITY; APOPTOTIC CELL DEATH; BORTEZOMIB; DRUG DELIVERY; MESOPOROUS SILICA; NSCLC;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, SCANNING; NANOSPHERES; PYRAZINES; SILICON DIOXIDE; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84887023392     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.098     Document Type: Article

References (59)

1. Umar A., Dunn B.K., Greenwald P. Future directions in cancer prevention. Nat Rev Cancer 2012, 12:835-848.
2. Perez-Moreno P., Brambilla E., Thomas R., Soria J.C. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012, 18:2443-2451.
3. Houghton A.M. Mechanistic links between COPD and lung cancer. Nat Rev Cancer 2013, 13:233-245.
4. Oxnard G.R., Binder A., Janne P.A. New targetable oncogenes in non-small-cell lung cancer. JClin Oncol 2013, 31:1097-1104.
5. Murray S., Karavasilis V., Bobos M., Razis E., Papadopoulos S., Christodoulou C., et al. Molecular predictors of response to tyrosine kinase inhibitors in patients with non-small-cell lung cancer. JExp Clin Cancer Res 2012, 31:77.
6. Vilmar A.C., Sorensen J.B. Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives. Eur Respir Rev 2011, 20:45-52.
7. Varshavsky A. Three decades of studies to understand the functions of the ubiquitin family. Methods Mol Biol 2012, 832:1-11.
8. Maupin-Furlow J. Proteasomes and protein conjugation across domains of life. Nat Rev Microbiol 2012, 10:100-111.
9. Pagan J., Seto T., Pagano M., Cittadini A. Role of the ubiquitin proteasome system in the heart. Circ Res 2013, 112:1046-1058.
10. Micel L.N., Tentler J.J., Smith P.G., Eckhardt G.S. Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. JClin Oncol 2013, 31:1231-1238.
11. Mullard A. Next-generation proteasome blockers promise safer cancer therapy. Nat Med 2012, 18:7.
12. Wu W.K., Cho C.H., Lee C.W., Wu K., Fan D., Yu J., et al. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett 2010, 293:15-22.
13. Chen D., Frezza M., Schmitt S., Kanwar J., Dou Q.P. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011, 11:239-253.
14. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. Aphase 2 study of bortezomib in relapsed, refractory myeloma. NEngl J Med 2003, 348:2609-2617.
15. Richardson P.G., Weller E., Lonial S., Jakubowiak A.J., Jagannath S., Raje N.S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
16. Kelly K.R., Espitia C.M., Mahalingam D., Oyajobi B.O., Coffey M., Giles F.J., et al. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene 2012, 31:3023-3038.
17. Laubach J., Richardson P. Hematology: bortezomib and dexamethasone induction for multiple myeloma. Nat Rev Clin Oncol 2011, 8:8-10.
18. Barr P., Fisher R., Friedberg J. The role of bortezomib in the treatment of lymphoma. Cancer Invest 2007, 25:766-775.
19. Kane R.C., Dagher R., Farrell A., Ko C.W., Sridhara R., Justice R., et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007, 13:5291-5294.
20. Koprivnikar J.L., Cheson B.D. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma. Future Oncol 2012, 8:359-371.
21. Scagliotti G.V., Germonpre P., Bosquee L., Vansteenkiste J., Gervais R., Planchard D., et al. Arandomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 2010, 68:420-426.
22. Lynch T.J., Fenton D., Hirsh V., Bodkin D., Middleman E.L., Chiappori A., et al. Arandomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. JThorac Oncol 2009, 4:1002-1009.
23. Davies A.M., Ho C., Metzger A.S., Beckett L.A., Christensen S., Tanaka M., et al. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. JThorac Oncol 2007, 2:1112-1116.
24. Voortman J., Checinska A., Giaccone G. The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. Mol Cancer 2007, 6:73.
25. Ceresa C., Giovannetti E., Voortman J., Laan A.C., Honeywell R., Giaccone G., et al. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. Mol Cancer Ther 2009, 8:1026-1036.
26. Nagji A.S., Cho S.H., Liu Y., Lee J.K., Jones D.R. Multigene expression-based predictors for sensitivity to vorinostat and velcade in non-small cell lung cancer. Mol Cancer Ther 2010, 9:2834-2843.
27. Lilenbaum R., Wang X., Gu L., Kirshner J., Lerro K., Vokes E. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. JClin Oncol 2009, 27:4487-4491.
28. Besse B., Planchard D., Veillard A.S., Taillade L., Khayat D., Ducourtieux M., et al. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer 2012, 76:78-83.
29. Li T., Ho L., Piperdi B., Elrafei T., Camacho F.J., Rigas J.R., et al. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 2010, 68:89-93.
30. Song I.S., Kim H.K., Lee S.R., Jeong S.H., Kim N., Ko K.S., et al. Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells. Int J Cancer 2013, 133:1357-1367.
31. Chauhan D., Tian Z., Nicholson B., Kumar K.G., Zhou B., Carrasco R., et al. Asmall molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 2012, 22:345-358.
32. Vanderloo J.P., Pomplun M.L., Vermeulen L.C., Kolesar J.M. Stability of unused reconstituted bortezomib in original manufacturer vials. JOncol Pharm Pract 2011, 17:400-402.
33. Wei W., Yue Z.G., Qu J.B., Yue H., Su Z.G., Ma G.H. Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an invitro evaluation. Nanomedicine 2010, 5:589-596.
34. Schwartz R., Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park) 2004, 18:14-21.
35. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
36. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
37. Mamaeva V., Sahlgren C., Linden M. Mesoporous silica nanoparticles in medicine-recent advances. Adv Drug Deliv Rev 2013, 65:689-702.
38. Yang P., Gai S., Lin J. Functionalized mesoporous silica materials for controlled drug delivery. Chem Soc Rev 2012, 41:3679-3698.
39. Vivero-Escoto J.L., Slowing, Trewyn B.G., Lin V.S. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small 2010, 6:1952-1967.
40. Han L., Zhou Y., He T., Song G., Wu F., Jiang F., et al. One-pot morphology-controlled synthesis of various shaped mesoporous silica nanoparticles. JMater Sci 2013, 48:5718-5726.
41. Song G., Li C., Hu J., Zou R., Xu K., Han L., et al. Asimple transformation from silica core-shell-shell to yolk-shell nanostructures: a useful platform for effective cell imaging and drug delivery. JMater Chem 2012, 22:17011-17018.
42. 2 core-shell nanocomposites: combining photothermal- and chemotherapies with infrared thermal imaging for cancer treatment. Adv Funct Mater 2013, 23:4281-4292.
43. Conference on the primary prevention of cancer: assessment of risk factors and future directions. Prev Med 1980, 9:165-332.
44. Wang T., Chai F., Fu Q., Zhang L., Liu H., Li L., et al. Uniform hollow mesoporous silica nanocages for drug delivery invitro and invivo for liver cancer therapy. JMater Chem 2011, 21:5299-5306.
45. Li L., Tang F., Liu H., Liu T., Hao N., Chen D., et al. Invivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano 2010, 4:6874-6882.
46. Wu H., Zhang S., Zhang J., Liu G., Shi J., Zhang L. Ahollow-core, magnetic, and mesoporous double-shell nanostructure: in situ decomposition/reduction synthesis, bioimaging, and drug-delivery properties. Adv Funct Mater 2011, 21:1850-1862.
47. Qi G., Wang Y., Estevez L., Switzer A.K., Duan X., Yang X., et al. Facile and scalable synthesis of monodispersed spherical capsules with a mesoporous shell. Chem Mater 2010, 22:2693-2695.
48. Lei J., Wang L., Zhang J. Superbright multifluorescent core-shell mesoporous nanospheres as trackable transport carrier for drug. ACS Nano 2011, 5:3447-3455.
49. Liu H.M., Wu S.H., Lu C.W., Yao M., Hsiao J.K., Hung Y., et al. Mesoporous silica nanoparticles improve magnetic labeling efficiency in human stem cells. Small 2008, 4:619-626.
50. Sekhar C.K., Sudhakar P., Reddy G.R., Babu P.V., Swamy N.L. Anew UV-method for determination of bortezomib in bulk and pharmaceutical dosage form. Int J Pharm Bio Sci 2013, 3:623-627.
51. Hong Y.S., Hong S.W., Kim S.M., Jin D.H., Shin J.S., Yoon D.H., et al. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1. Int J Oncol 2012, 41:76-82.
52. Tamura D., Arao T., Tanaka K., Kaneda H., Matsumoto K., Kudo K., et al. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition. Cancer Sci 2010, 101:1403-1408.
53. Yang F., Jove V., Chang S., Hedvat M., Liu L., Buettner R., et al. Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-kB signaling, and synergizes with an ERK inhibitor. Cancer Biol Ther 2012, 13:349-357.
54. Lioni M., Noma K., Snyder A., Klein-Szanto A., Diehl J.A., Rustgi A.K., et al. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol Cancer Ther 2008, 7:2866-2875.
55. Klionsky D.J., Abeliovich H., Agostinis P., Agrawal D.K., Aliev G., Askew D.S., et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008, 4:151-175.
56. Huang C.L., Yokomise H., Miyatake A. Clinical significance of the p53 pathway and associated gene therapy in non-small cell lung cancers. Future Oncol 2007, 3:83-93.
57. Neukirchen J., Meier A., Rohrbeck A., Garcia-Pardillos G., Steidl U., Fenk R., et al. The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells. Cancer Gene Ther 2007, 14:431-439.
58. Jiang T., Zhou C., Gu J., Liu Y., Zhao L., Li W., et al. Enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated salmonella carrying a plasmid co-expressing p53 gene and mdm2 siRNA. Cancer Lett 2013, 337:133-142.
59. Xu Q., Leong J., Chua Q.Y., Chi Y.T., Chow P.K., Pack D.W., et al. Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials 2013, 34:5149-5162.